X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Neumora's investigation product NMRA-266 is a positive allosteric modulator of the M4 muscarinic receptor. It is being evaluated in the clinical trials for the treatment of Schizophrenia.
Lead Product(s): NMRA-266
Therapeutic Area: Psychiatry/Psychology Product Name: NMRA-266
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia.
Lead Product(s): NMRA-266
Therapeutic Area: Psychiatry/Psychology Product Name: NMRA-266
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
NMRA-140 (navacaprant) is a highly selective, novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for MDD.
Lead Product(s): Navacaprant
Therapeutic Area: Psychiatry/Psychology Product Name: NMRA-140
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BlackThorn Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
The funding will support the advancement of a broad clinical and preclinical pipeline of novel precision medicine candidates including BTRX-335140 (NMRA-140) for neuropsychiatric disorders and neurodegenerative diseases and the development of precision neuroscience platform.
Lead Product(s): Navacaprant
Therapeutic Area: Psychiatry/Psychology Product Name: BTRX-335140
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Abu Dhabi Growth Fund
Deal Size: $112.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 11, 2022
Details:
The research collaboration will support ongoing preclinical work at WCNDD to advance backup series of highly selective M4 receptor PAMs. Neumora is progressing the lead series toward the nomination of a development candidate.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Vanderbilt University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 17, 2022
Details:
Through the advancement of data science tools and biopsies, the field progressed to understand that these were diseases driven by biological mechanisms and genetics.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration October 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
